You are here: Home: Audio Program Guide: LCU 2 | 2007 Audio: LCU 2 | 2007

  Go to interview with Corey J Langer, MD
Go to Roundtable Discussion
Go to interview with Joan H Schiller, MD
Go to interview with Craig Reynolds, MD
   
  To listen to individual tracks, click the on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
 
Lager, MD Corey J Langer, MD
Medical Director of Thoracic Oncology and Head and Neck Oncology
Vice Chair of the Radiation Therapy Oncology Group
Fox Chase Cancer Center
Philadelphia, Pennsylvania

  
  Click here to download entire interview  
Track 1 Introduction
Track 2 Adjuvant chemotherapy in Stage IB non-small cell lung cancer (NSCLC): Update of CALGB-9633
Track 3 Clinical implications of CALGB-9633 and the treatment of Stage IB disease
Track 4 Lung Adjuvant Cisplatin Evaluation (LACE): A pooled analysis of five randomized clinical trials including 4,584 patients
Track 5 Adjuvant chemotherapy in elderly patients: Analysis of CAN-NCIC-BR10
Track 6 Side effects of bevacizumab and eligibility criteria for adjuvant trials
Track 7 ECOG-E1505: Adjuvant chemotherapy with or without bevacizumab in patients with completely resected Stage IB-IIIA NSCLC
Track 8 Incorporation of bevacizumab into the treatment of advanced NSCLC
Track 9 Phase II trial of docetaxel with the multikinase inhibitor ZD6474 as second-line therapy
Track 10 Use of bevacizumab in patients with treated brain metastases
Track 11 Potential relationship between hemorrhage and response to bevacizumab
Track 12 Multicenter, randomized trial of bevacizumab with chemotherapy (docetaxel or pemetrexed) or erlotinib compared to chemotherapy alone for recurrent or refractory NSCLC
Track 13 Predictors of response to the EGFR tyrosine kinase inhibitors (TKIs)
Track 14 Use of erlotinib in nonsmokers with early or locally advanced NSCLC audio
Track 15 Hoosier Oncology Group trial: Cisplatin/etoposide/radiation therapy with or without consolidation docetaxel in advanced Stage III NSCLC audio
Track 16 Potential role for nanoparticle albumin-bound (nab) paclitaxel in NSCLC audio
Track 17 Decreasing morbidity in patients with locally advanced disease undergoing combined-modality therapy audio
 
  Roundtable Discussion


  
  Click here to download entire interview  
Track 1 Introduction
Track 2 Adjustment for competing causes of mortality in lung cancer and feasibility of the development of an Adjuvant! Online-type model in lung cancer
Track 3 Impact of CALGB-9633 adjuvant trial on clinical practice
Track 4 Role of surgical expertise and procedures in the prognosis of resected NSCLC
Track 5 Importance of thoracic oncology surgeons in the treatment of NSCLC
Track 6 Use of cisplatin/docetaxel versus cisplatin/vinorelbine as adjuvant therapy
Track 7 Bevacizumab-associated toxicity in ECOG-E4599
Track 8 Potential side effects and toxicity associated with adjuvant bevacizumab
Track 9 Challenges in the completion of adjuvant clinical trials in lung cancer
Track 10 Erlotinib for select patients with NSCLC in the adjuvant setting
Track 11 Differences in decision-making with regard to adjuvant treatment of breast and lung cancer
Track 12 Cavitation and bleeding and bevacizumab-associated antitumor effect
Track 13 Case discussion: An 80-year-old man with Stage IIIB NSCLC and preexisting peripheral neuropathy
Track 14 Use of the SWOG-S9504 regimen of chemoradiation therapy followed by consolidation docetaxel for Stage IIIB disease
 
Schiller, MD Joan H Schiller, MD
Professor and Division Chief, Hematology/Oncology
Deputy Director, Simmons Comprehensive Cancer Center
UT Southwestern Medical Center
Dallas, Texas

  
  Click here to download entire interview  
Track 1 Introduction
Track 2 ECOG-E4599: Efficacy and toxicity of carboplatin/paclitaxel with or without bevacizumab for advanced nonsquamous-cell NSCLC
Track 3 Potential factors involved in bevacizumab-associated hemoptysis
Track 4 Use of bevacizumab in the metastatic setting
Track 5 Risk of bevacizumab-associated hemoptysis and use of bevacizumab in patients with treated brain metastases
Track 6 Gender differences in lung cancer and response to treatment
Track 7 Clinical trial strategies in small cell lung cancer (SCLC)
Track 8 ECOG-E1505 adjuvant trial of chemotherapy with or without bevacizumab in Stage IB-IIIA NSCLC
Track 9 Adjuvant chemotherapy in Stage IB NSCLC: Update of CALGB-9633
Track 10 Use of standard-dose chemotherapy concurrently with radiation therapy in the treatment of Stage IIIB NSCLC
Track 11 Tolerability of consolidation docetaxel after concurrent chemoradiation therapy for Stage IIIB NSCLC audio
Track 12 Factors influencing patient acceptance of adjuvant chemotherapy for NSCLC audio
Track 13 Studies evaluating radiation therapy/bevacizumab for Stage III disease audio
Track 14 Factors in decision-making about the use of the EGFR TKI erlotinib audio

 
Reynolds, MD Craig Reynolds, MD
Development Chair
Lung Cancer Research Committee
US Oncology Research
Ocala Oncology Center
Ocala, Florida

  
  Click here to download entire interview  
Track 1 Introduction
Track 2 Development of novel TKIs in NSCLC
Track 3 Combination therapy with bevacizumab and erlotinib
Track 4 Predictors of response to the EGFR TKIs
Track 5 Phase II trial of carboplatin, nab paclitaxel and bevacizumab for patients with nonsquamous-cell NSCLC
Track 6 Secreted protein acidic and rich in cysteine (SPARC), caveolin-1 and enhanced delivery of nab paclitaxel
Track 7 Clinical trial results with MUC1 and MAGE vaccines in NSCLC
Track 8 Clinical research strategies to identify targets for chemotherapy and novel agents
Track 9 Evaluation of the novel anthracycline amrubicin in the treatment of SCLC
Track 10 Incorporation of bevacizumab into the treatment of NSCLC
Track 11 Lung cancer in smokers and nonsmokers: Implications for treatment approaches audio